Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences, Inc.

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. 

Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. 

Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. 

Interested in joining our team? Please check out our jobs at
https://cariboubio.bamboohr.com/jobs/

Intellia Therapeutics

Janus Henderson Investors

LifeSci Venture Partners

Maverick Ventures

Heritage Group

Ridgeback Capital

Farallon Capital Management

AbbVie Biotech Ventures

Adage Capital Management

Avego Bioscience Capital

Avidity Partners

Caribou Biosciences

Join our VP, clinical development Socorro Portella, MD, and director of clinical research Ashley Hammad, AG-CNS, tomorrow at the #CRISPR 2.0 workshop, A 101 in First-in-Human CRISPR Trials taking place at 1:00pm ET tomorrow.

Kevin Liao, associate director, supply chain, will lead a workshop at the Donor Selection and Cell Source Summit. Join him on Tuesday, Nov. 28 at 1 pm ET.

The Caribou team will be presenting at the 4th Annual #CRISPR 2.0 Conference next week in Boston! Socorro Portella, MD, and Ashley Hammad, RN, will lead a workshop on Tuesday, Nov. 28 at 1 pm ET and Enrique Zudaire, PhD, will present on Thursday, Nov. 30 at 11:45 am ET. #CRISPR #CARTcell

Members of the Caribou team enjoyed an incredible night celebrating the accomplishments of Paul Donohoue, associate director of platform discovery and co-inventor of Caribou’s chRDNA technology, and the other nine esteemed winners of the 2023 Biocom California Catalyst Awards. Join us, once again, in congratulating Paul on this very well-deserved recognition of his innovation and scientific advancement in #CRISPR genome-editing technologies.  

Want to learn more about one of Paul's inventions? Check it out here: https://lnkd.in/gbEsNexH

Tune in for our company presentation by President and CEO Rachel Haurwitz, PhD, at the Jefferies London Healthcare Conference. A link to the webcast is on the investor section of our website: https://lnkd.in/gjSwyTzc

Caribou would be nothing without the incredible people who make up #theHerd. We are starting a new series to highlight Caribou’s leaders and explore their team’s impact, why they joined Caribou, and what drives them to develop allogeneic CAR-T cell therapies. We start the series with Enrique Zudaire, PhD. Watch the video to learn more about Kike!

Ahead of Veterans Day, we’d like to extend our gratitude to American veterans, especially those who are part of #TheHerd. Thank you for your service. #VeteransDay

This year, we have advanced our programs to build value across the pipeline and position Caribou as a leader in the allogeneic CAR-T cell therapy space. Learn more about our progress in our Q3 2023 financial results here: https://lnkd.in/gcXfDtbf #CRISPR #CARTcelltherapy

We are excited to announce the appointment of Jagannath Sundar, MD, to our scientific advisory board. We welcome Dr. Jagannath and his insights as a renowned expert in the treatment of #multiplemyeloma.
https://lnkd.in/eM47dKkA

Don’t miss Caribou Biosciences at upcoming investor conferences—tune in to available webcasts here: https://lnkd.in/gjSwyTzc

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-23.43M -	-34.31M 46.42%	-66.92M 95.07%	-99.42M 48.56%	-102.07M 2.66%
depreciation and amortization	751K -	900K 19.84%	984K 9.33%	1.62M 64.84%	3.52M 117.32%
deferred income tax		803K -	-1.52M 289.54%	-95K 93.76%	177K 286.32%
stock based compensation	1.23M -	1.00M 18.80%	3.45M 244.21%	11.72M 239.69%	13.75M 17.36%
change in working capital	-8.27M -	177K 102.14%	29.07M 16,322.03%	-4.20M 114.46%	-7.32M 74.07%
accounts receivables	617K -	-146K 123.66%	-1.00M 586.99%	951K 194.82%	805K 15.35%
inventory	-2.22M -	1.35M 160.93%	-2.20M 262.36%
accounts payables	1.18M -	43K 96.34%	1.14M 2,548.84%	-2.72M 338.89%	1.82M 166.85%
other working capital	-7.84M -	-1.07M 86.28%	31.13M 2,995.91%	-2.43M 107.82%	-9.94M 308.46%
other non cash items	-2.29M -	-1.79M 21.98%	2.43M 235.61%	-584K 124.07%	-1.35M 132.02%
net cash provided by operating activities	-32.01M -	-33.22M 3.78%	-32.52M 2.10%	-90.97M 179.73%	-93.29M 2.56%
investments in property plant and equipment	-884K -	-1.31M 48.76%	-3.12M 137.34%	-7.05M 126.02%	-11.61M 64.63%
acquisitions net		10K -		600K -	-4.42M 837.50%
purchases of investments		-10K -	-173.28M 1,732,660.00%	-339.06M 95.68%	-394.76M 16.43%
sales maturities of investments	28.12M -	7.67M 72.73%		252.87M -	338.19M 33.74%
other investing activites		10K -		-600K -	4.42M 837.50%
net cash used for investing activites	27.23M -	6.36M 76.63%	-176.40M 2,872.23%	-93.25M 47.14%	-68.18M 26.88%
debt repayment	-45K -	-113K 151.11%	-119K 5.31%
common stock issued	217K -	270K 24.42%	321.02M 118,796.30%	2.13M 99.34%	154.30M 7,133.85%
common stock repurchased
dividends paid
other financing activites	172K -	1.58M 817.44%	112.53M 7,031.05%
net cash used provided by financing activities	172K -	1.74M 908.72%	433.43M 24,881.50%	2.13M 99.51%	154.30M 7,133.85%
effect of forex changes on cash
net change in cash	-4.60M -	-25.12M 445.90%	224.51M 993.87%	-182.08M 181.10%	-7.18M 96.06%
cash at beginning of period	45.67M -	41.07M 10.07%	15.95M 61.16%	240.47M 1,407.34%	58.34M 75.74%
cash at end of period	41.07M -	15.95M 61.16%	240.47M 1,407.34%	58.38M 75.72%	51.16M 12.37%
operating cash flow	-32.01M -	-33.22M 3.78%	-32.52M 2.10%	-90.97M 179.73%	-93.29M 2.56%
capital expenditure	-884K -	-1.31M 48.76%	-3.12M 137.34%	-7.05M 126.02%	-11.61M 64.63%
free cash flow	-32.89M -	-34.53M 4.99%	-35.64M 3.21%	-98.02M 175.03%	-104.90M 7.02%

COM:CARIBOUBIO

Caribou Biosciences

Last Close

1.96

21/11 21:00

Market Cap

153.54M

Beta: -

Volume Today

1.10M

Avg: -

Preview